Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.16Last Year’s EPS
-0.07Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: 42.24%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflects strong performance and growth in revenue, successful product launches, and positive clinical developments. However, challenges remain with competitive market pressures and ongoing development of the subcutaneous formulation.Company Guidance
In the recent conference call, TG Therapeutics provided guidance that highlighted significant achievements and future plans for BRIUMVI. For fiscal year 2024, the company reported U.S. revenues of $310 million, exceeding their target, and projected strong growth into 2025 with a revenue estimate of $525 million. The company discussed the successful launch of BRIUMVI in the U.S. and Europe, with a significant 160% growth in fourth-quarter U.S. net sales year-over-year. Further, TG Therapeutics emphasized their strategic focus on enhancing patient experience by developing a subcutaneous formulation of BRIUMVI, targeting a pivotal trial initiation by mid-2025. The guidance also outlined plans for clinical trials, including a Phase 1 study for BRIUMVI in myasthenia gravis and an exploratory study for azer-cel in multiple sclerosis. Operating expenses for 2024 were well-controlled at $206 million, and the company is financially positioned with $311 million in cash to support ongoing initiatives. Overall, TG Therapeutics expressed confidence in their ability to sustain growth and expand BRIUMVI's market presence.Record-Breaking Revenue and Growth
Full year 2024 U.S. revenues of $310 million exceeded target guidance, marking approximately 250% growth versus 2023. Q4 U.S. net sales were $103.6 million, representing 24% growth quarter-over-quarter.
Successful Launch and Expansion of BRIUMVI
BRIUMVI was successfully launched in various EU countries and the U.K. through partner Neuraxpharm, with positive feedback from the EU market.
Positive Clinical Data and Development
Updated data from the ENHANCE study showed consistent safety and tolerability with a 30-minute infusion. Preliminary data supports a potential subcutaneous formulation with at least every other month dosing.
Patent Protection and Pipeline Expansion
Three new patents issued in 2024 provide protection for BRIUMVI through 2042. Partnership with Precision BioSciences to develop azer-cel for autoimmune diseases was announced.
---
TGTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TGTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $30.09 | $34.42 | +14.39% |
| Nov 04, 2024 | $26.90 | $24.36 | -9.44% |
| Aug 06, 2024 | $17.21 | $20.58 | +19.58% |
| May 01, 2024 | $13.66 | $15.88 | +16.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does TG Therapeutics (TGTX) report earnings?
TG Therapeutics (TGTX) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is TG Therapeutics (TGTX) earnings time?
TG Therapeutics (TGTX) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TGTX EPS forecast?
TGTX EPS forecast for the fiscal quarter 2025 (Q1) is 0.16.
---